StreetInsider.com News Articles

Form 3 Merck & Co., Inc. For: Mar 02 Filed by: Foard Brian

Thu, 12 Mar 2026 13:53:00 -0400

si-local-file:///var/storage/secattach/20260312/26152139.html

Form 3 Merck & Co., Inc. For: Mar 02 Filed by: Foard Brian

Thu, 12 Mar 2026 13:53:00 -0400

si-local-file:///var/storage/secattach/20260312/26152139.html

Merck (MRK) PT Raised to $150 at Wells Fargo

Thu, 12 Mar 2026 07:05:19 -0400

Wells Fargo analyst Mohit Bansal raised the price target on Merck (NYSE: MRK) to $150.00 (from $135.00) while maintaining a Overweight rating.

The analyst comments "We think Sac-TMT could become the best-in-class TROP2 ADC and replace chemo in multiple lung, breast, and gyn indications. In this report we examine Sac-TMT's clinical data and how it compares to other ADCs and standard of care. PT: $150 Differentiated safety could unlock durability and >$15B peak unadjusted opportunity. Key Points from our report 1) Data suggests best-in-class safety/tolerability and durability among TROP2 ADCs, 2) Multiple indications beyond Lung and Breast cancer could support $15B+

Merck (MRK) PT Raised to $150 at Wells Fargo

Thu, 12 Mar 2026 07:05:19 -0400

Wells Fargo analyst Mohit Bansal raised the price target on Merck (NYSE: MRK) to $150.00 (from $135.00) while maintaining a Overweight rating.

NeOnc Technologies sets phase 2 dose for brain cancer drug NEO212

Wed, 04 Mar 2026 08:00:33 -0400

NeOnc Technologies Holdings Inc. (NASDAQ: NTHI) announced it has established the recommended phase 2 dose for its oral brain cancer treatment NEO212 after completing the dose-escalation portion of its phase 1/2 clinical trial.

The company notified the FDA that the maximum tolerated dose was reached at 810 mg following a second dose-limiting toxicity event. The recommended phase 2 dose has been set at 610 mg, with the phase 2a metastasis cohort starting at 400 mg.

NEO212 is a bio-conjugated oral therapy that combines temozolomide, the current standard treatment for glioblastoma, with NEO100, a proprietary form of perillyl alcohol. The drug is designed

NeOnc Technologies sets phase 2 dose for brain cancer drug NEO212

Wed, 04 Mar 2026 08:00:33 -0400

NEO212 is a bio-conjugated oral therapy that combines temozolomide, the current standard treatment for glioblastoma, with NEO100, a proprietary form of perillyl alcohol. The drug is designed

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m.

Wed, 04 Mar 2026 08:00:00 -0400

CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company’s novel oral bio-conjugated therapy and will host a conference call to discuss the data today at 9:00am ET.

NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m.

Wed, 04 Mar 2026 08:00:00 -0400

NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m.

Wed, 04 Mar 2026 08:00:00 -0400

NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m.

Wed, 04 Mar 2026 08:00:00 -0400

NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

Mon, 02 Mar 2026 17:31:00 -0400

LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/OHARA Pharmaceutical), Tovecimig (CTX-009) (Compass Therapeutics), Lenvatinib mesylate (LENVIMA) (Merck/Eisai), and others will further boost the market growth.